ZUG, SWITZERLAND — AVEA, the longevity supplement startup with the aim to improve healthspan, announces the closing of a 2.5 million CHF seed financing round led by Maximon, The Longevity Company Builder and its Longevity Co-Investment Fund. The deal was made public in Davos during this year's "World Economic Forum" where Maximon hosted an event for investors in the field of longevity.
Dr. Tobias Reichmuth, serial entrepreneur and founding partner of Maximon, states: “The global longevity market is worth $8 trillion. The longevity field is the future of healthcare and we believe AVEA will play an important role in the industry.”
“As we are seeking to build and launch longevity companies with Maximon, Avea was a clear case for us to invest in. We are at an inflection point where people not only look at supplements to boost health and vitamin levels, but start to actively invest in a longer healthy lifespan. This is the opportunity that Avea is well positioned to capture and we are excited to be part of this story“ adds Caroline Wagner, chairwoman of the Board of Avea and founding partner of Maximon.
This first funding will support the company's rapid growth across Switzerland, Germany, Austria and the UK, power scientific research, propel the development of innovative longevity-focused supplements and help establish the brand as a leader in Europe.
After a year of research, AVEA launched its first products in February 2022. The first formulation is a synergistic blend of ingredients which reflect the latest research in ageing and healthspan. AVEA has enlisted award-winning scientists and researchers in the field of longevity to produce the highest quality, comprehensive and scientifically-backed supplement line on the European market for those who wish to optimize their long-term health as well as slow and even reverse some of the signs of ageing.
"Long-term health is an investment, not an expense. Next to a balanced diet, regular exercise, hot and cold therapy and quality sleep, a longevity supplement regimen is essential to support and optimize the healthy ageing process”, says Scientist and Co-founder Sophie Chabloz.
AVEA’s strategy is to leverage a science-based approach to help customers make sense of the overwhelming health and wellness supplement market. The main idea behind AVEA’s products is to focus on ingredients that act in synergy to slow ageing at the cellular level, because when your cells work better, your whole body works better.
AVEA has been named by Sifted one of 13 longevity startups to watch according to top investors.
AVEA’s mission is to support people’s health and longevity goals with research-backed longevity supplements, providing effective healthy ageing and rejuvenation solutions to help people feel energized and youthful for as long as possible. AVEA believes that everyone deserves to achieve vibrant health throughout their years so they can keep learning, achieving new goals, and enjoying life without feeling limited by their age. AVEA’s supplements are available for order at https://avea-life.com/.
Maximon is a longevity company builder based in Switzerland with the mission to become the leading player in the field of longevity and healthy lifespan by empowering entrepreneurs to build impactful, science-based and scalable companies, which provide healthy ageing and rejuvenation solutions. More information about Maximon can be found on https://www.maximon.com/
Contact:Teresa Budetta - Chief Marketing Officer Avea.
Phone number: +33 671 366297